Hepatic progenitor cells activation, fibrosis, and adipokines production in pediatric nonalcoholic fatty liver disease

Hepatology

Volumn 56, Issue 6, 2012, Pages 2142-2153

  Nobili, Valerio ^a   Carpino, Guido ^b   Alisi, Anna ^a   Franchitto, Antonio ^c,d   Alpini, Gianfranco ^e   De Vito, Rita ^a   Onori, Paolo ^f   Alvaro, Domenico ^d,g   Gaudio, Eugenio ^c  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b UNIVERSITY OF ROME FORO ITALICO   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d Eleonora Lorillard Spencer Cenci Foundation   (Italy)

^e TEXAS A M COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF L'AQUILA   (Italy)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; GLUCAGON LIKE PEPTIDE 1; RESISTIN;

ADOLESCENT; APOPTOSIS; ARTICLE; CELL ACTIVATION; CELL COMPARTMENTALIZATION; CELL CYCLE ARREST; CELL EXPANSION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FATTY LIVER; FEMALE; GENE OVEREXPRESSION; HEPATIC PROGENITOR CELL; HEPATITIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER CELL; LIVER FIBROSIS; MALE; NAFLD ACTIVITY SCORE; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PEDIATRICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RATING SCALE; RECEPTOR DOWN REGULATION; SCHOOL CHILD; STEM CELL;

ADIPONECTIN; ADOLESCENT; APOPTOSIS; CELL COUNT; CELL CYCLE CHECKPOINTS; CHILD; FATTY LIVER; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HEPATITIS; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; RESISTIN; SEVERITY OF ILLNESS INDEX; STEM CELLS;

EID: 84867723466     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25742     Document Type: Article

References (37)

1. Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2010; 7: 195-203.
2. Alisi A, Manco M, Vania A, Nobili V. Pediatric nonalcoholic fatty liver disease in 2009. J Pediatr 2009; 155: 469-474.
3. Dunn W, Schwimmer JB. The obesity epidemic and nonalcoholic fatty liver disease in children. Curr Gastroenterol Rep 2008; 10: 67-72.
4. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. HEPATOLOGY 2010; 51: 1820-1832.
5. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. HEPATOLOGY 2010; 52: 1836-1846.
6. Roskams T, Yang SQ, Koteish A, Durnez A, DeVos R, Huang X, et al. Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease. Am J Pathol 2003; 163: 1301-1311.
7. Spee B, Carpino G, Schotanus BA, Katoonizadeh A, Vander Borght S, Gaudio E, et al. Characterisation of the liver progenitor cell niche in liver diseases: potential involvement of Wnt and Notch signalling. Gut 2010; 59: 247-257.
8. Roskams TA, Theise ND, Balabaud C, Bhagat G, Bhathal PS, Bioulac-Sage P, et al. Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. HEPATOLOGY 2004; 39: 1739-1745.
9. Gaudio E, Carpino G, Cardinale V, Franchitto A, Onori P, Alvaro D. New insights into liver stem cells. Dig Liver Dis 2009; 41: 455-462.
10. Theise ND, Kuwahara R. The tissue biology of ductular reactions in human chronic liver disease. Gastroenterology 2007; 133: 350-352.
11. Richardson MM, Jonsson JR, Powell EE, Brunt EM, Neuschwander-Tetri BA, Bhathal PS, et al. Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. Gastroenterology 2007; 133: 80-90.
12. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. HEPATOLOGY 2005; 41: 1313-1321.
13. Nobili V, Marcellini M, Devito R, Ciampalini P, Piemonte F, Comparcola D, et al. NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice. HEPATOLOGY 2006; 44: 458-465.
14. Marra F, Bertolani C. Adipokines in liver diseases. HEPATOLOGY 2009; 50: 957-969.
15. Bertolani C, Sancho-Bru P, Failli P, Bataller R, Aleffi S, DeFranco R, et al. Resistin as an intrahepatic cytokine: overexpression during chronic injury and induction of proinflammatory actions in hepatic stellate cells. Am J Pathol 2006; 169: 2042-2053.
16. Kaser S, Moschen A, Cayon A, Kaser A, Crespo J, Pons-Romero F, et al. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 2005; 54: 117-121.
17. Nobili V, Manco M, Devito R, Di Ciommo V, Comparcola D, Sartorelli MR, et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. HEPATOLOGY 2008; 48: 119-128.
18. Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. HEPATOLOGY 2011; 53: 810-820.
19. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001; 21: 3-16.
20. Katoonizadeh A, Nevens F, Verslype C, Pirenne J, Roskams T. Liver regeneration in acute severe liver impairment: a clinicopathological correlation study. Liver Int 2006; 26: 1225-1233.
21. Fausto N. Liver regeneration and repair: hepatocytes, progenitor cells, and stem cells. HEPATOLOGY 2004; 39: 1477-1487.
22. Turanyi E, Dezso K, Csomor J, Schaff Z, Paku S, Nagy P. Immunohistochemical classification of ductular reactions in human liver. Histopathology 2010; 57: 607-614.
23. Nobili V, Parola M, Alisi A, Marra F, Piemonte F, Mombello C, et al. Oxidative stress parameters in paediatric non-alcoholic fatty liver disease. Int J Mol Med 2011; 26: 471-476.
24. Alvaro D, Mancino MG, Glaser S, Gaudio E, Marzioni M, Francis H, et al. Proliferating cholangiocytes: a neuroendocrine compartment in the diseased liver. Gastroenterology 2007; 132: 415-431.
25. Glaser SS, Gaudio E, Miller T, Alvaro D, Alpini G. Cholangiocyte proliferation and liver fibrosis. Expert Rev Mol Med 2009; 11: e7.
26. Omenetti A, Porrello A, Jung Y, Yang L, Popov Y, Choi SS, et al. Hedgehog signaling regulates epithelial-mesenchymal transition during biliary fibrosis in rodents and humans. J Clin Invest 2008; 118: 3331-3342.
27. Nobili V, Alisi A, Vania A, Tiribelli C, Pietrobattista A, Bedogni G. The pediatric NAFLD fibrosis index: a predictor of liver fibrosis in children with non-alcoholic fatty liver disease. BMC Med 2009; 7: 21.
28. Nobili V, Parkes J, Bottazzo G, Marcellini M, Cross R, Newman D, et al. Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease. Gastroenterology 2009; 136: 160-167.
29. Saxena NK, Ikeda K, Rockey DC, Friedman SL, Anania FA. Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. HEPATOLOGY 2002; 35: 762-771.
30. Beier JI, Guo L, von Montfort C, Kaiser JP, Joshi-Barve S, Arteel GE. New role of resistin in lipopolysaccharide-induced liver damage in mice. J Pharmacol Exp Ther 2008; 325: 801-808.
31. She H, Xiong S, Hazra S, Tsukamoto H. Adipogenic transcriptional regulation of hepatic stellate cells. J Biol Chem 2005; 280: 4959-4967.
32. Lumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. J Clin Invest 2011; 121: 2111-2117.
33. Spencer M, Yao-Borengasser A, Unal R, Rasouli N, Gurley CM, Zhu B, et al. Adipose tissue macrophages in insulin-resistant subjects are associated with collagen VI and fibrosis and demonstrate alternative activation. Am J Physiol Endocrinol Metab 2010; 299: E1016-E1027.
34. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007; 87: 1409-1439.
35. Ayala JE, Bracy DP, James FD, Burmeister MA, Wasserman DH, Drucker DJ. Glucagon-like peptide-1 receptor knockout mice are protected from high-fat diet-induced insulin resistance. Endocrinology 2010; 151: 4678-4687.
36. Lee YS, Shin S, Shigihara T, Hahm E, Liu MJ, Han J, et al. Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis. Diabetes 2007; 56: 1671-1679.
37. Marzioni M, Alpini G, Saccomanno S, Candelaresi C, Venter J, Rychlicki C, et al. Glucagon-like peptide-1 and its receptor agonist exendin-4 modulate cholangiocyte adaptive response to cholestasis. Gastroenterology 2007; 133: 244-255.